AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02831465 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Subjects
Description: Subjects with normal lung function performed MVV at increasing breathing frequencies and maximal tidal volume, from 10 to 100 cycles per minute. Inspiratory capacity (IC) was measured at rest and after each 12 seconds of MVV in order to detect DH. From the moment DH appeared at a given frequency, only one additional MVV at a higher breathing frequency was conducted to confirm DH.
Study NCT02977104 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Maestro ECG
Description: Telemetry is obtained through the Maestro handheld ECG device.
Study NCT03581331 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: orthoptic balance
Description: Measurement of visual acuity by far: Monocular measurement, right eye, left eye and binocular Measurement of visual acuity closely: Monocular measurement, right eye, left eye and binocular Corneal reflection method or Hirschberg: Analysis of the corneal reflection after fixation of a point of fixation of light from a distance, then from near.~Cover-Test: Study of the restitution movement following the fixation of the fixation point
Study NCT02944916 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IryPump R Set
Study NCT02485080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simeprevir
Study NCT02485080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Study NCT02770521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treprostinil
Description: Administered SC.
Study NCT02770521 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC.
Study NCT02770521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY900014
Description: Administered SC.
Study NCT02770521 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: Administered SC.
Study NCT01886521 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar drain
Study NCT01886521 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ventricular drain
Study NCT04031079 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearable tech with feedback
Description: an armwrist device measuring physical activity level. The user will receive information about their physical activity level through their smartphone
Study NCT04031079 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wearable tech without feedback
Description: an armwrist device measuring physical activity level, no reporting back to the user
Study NCT04031079 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rehabilitation program
Description: traditional inpatient rehabilitation program for overweight and obesity (lifestyle change program)
Study NCT04031079 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation program
Description: traditional inpatient rehabilitation program for overweight and obesity (lifestyle change program)
Study NCT03534479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyclonal IgG
Description: Measurement of vascular reactivity before and after Infusion of plyclonal Immunoglobulins G in patients with Common variable immunodeficiency
Study NCT03341260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac Potassium 50mg Tab.
Description: A 50 mg tablet of the medication to be taken one hour before initiation of endodontic treatment.
Study NCT03341260 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo will be taken one hour before initiation of endodontic treatment.
Study NCT03029013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib， 250 mg qd，po，after 7 days , paclitaxel (135-175 mg/m2) and platinum two drug standard chemotherapy, 21 days as a treatment cycle，during the chemotherapy of 7-21 days continue to offer the Apatinib. without disease progress, after 4 chemotherapy cycles, patients continue to accept the Apatinib maintenance treatment.
Study NCT03450928 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Peroral Endoscopic Myotomy (POEM)
Description: Peroral endoscopic myotomy (POEM) is a minimally invasive intervention for the treatment of esophageal achalasia.~POEM includes different steps:~1. Lifting of the esophageal mucosa, with the injection of saline solution, and mucosal incision on the esophageal body (approximately 12 or 7 cm above the esophagogastric junction, for about 1-2cm)~2. Advance of the endoscope into the submucosa, repeated submucosal injection and dissection of a submucosal tunnel into the distal esophagus up to 3 cm into the gastric wall.~3. Myotomy of the distal esophagus, cardia and gastric wall, starting 3 cm below the mucosal incision~4. After the completion of myotomy, and check for mucosal integrity, the mucosal incision is closed using endoscopic clips
Study NCT01668654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: retigabine/ezogabine
Description: retigabine/ezogabine will be administered three times a day (TID) as add-on therapy based on weight
Study NCT01084551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPM 962
Description: once a daily transdermal administration started at 2.25 mg/day to 4.5 mg/day for 13 weeks
Study NCT01084551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPM 962
Description: once a daily transdermal administration started at 2.25 mg/day to 6.75 mg/day for 13 weeks
Study NCT01084551 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of SPM 962
Description: once a daily transdermal administration for 13 weeks
Study NCT03806127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vibegron
Description: oral administration
Study NCT03806127 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral administration
Study NCT02137408 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Docosahexaenoic acid 200 mg
Description: Participants will be randomized to 200 mg docosahexaenoic acid daily (1-200mg capsule) PO beginning at 18-20 weeks gestation through 6 weeks post-partum.
Study NCT02137408 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docosahexaenoic acid 1000 mg
Description: Participants will be randomized to 1000 mg (5-200mg capsules) docosahexaenoic acid PO daily beginning at 18-20 weeks gestation through 6 weeks post-partum.
Study NCT02024971 — intervention group
Intervention type: DRUG
Intervention: Pioglitazone/metformin hydrochloride
Description: Pioglitazone/metformin hydrochloride combination tablets
Study NCT01467492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Description: Tablet
Study NCT01467492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Tablet
Study NCT01467492 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon Alfa-2a
Description: Subcutaneous Injection
Study NCT01891266 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-tourniquet assisted TKA
Description: The intervention group will undergo non-tourniquet assisted total knee arthroplasty, which means that blood flow to the lower limb is maintained throughout surgery.
Study NCT01891266 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Tourniquet assisted TKA
Description: The procedure involves the use of a tourniquet around the thigh. During surgery the tourniquet will be inflated above the systolic blood pressure to ensure a complete bloodless surgical field.
Study NCT01069445 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: VSL#3® probiotic blend
Description: Product should be administrated orally, 2 capsules b.i.d. on an empty stomach (at least 30 min. before lunch and dinner) with a glass of water
Study NCT01069445 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AISA-5203-L fruit extracted terpene
Description: Product should be administrated orally, the dosage depending from the body weight of the subject enrolled in the study as already stated : 1-2 pills three times a day with a meal and a large glass of water
Study NCT01069445 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Argan oil
Description: Product should be administrated orally, 25 ml once daily or during the day with a meal (bread, salad ...) and a large glass of water
Study NCT01069445 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Optimal Diet
Description: a dietician will train each subject (or the caregiver) to use the personalized diet on web platform.
Study NCT02981836 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational live attenuated varicella vaccine
Description: The investigational vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.
Study NCT02981836 — intervention group
Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: diluent of lyophilized vaccine
Description: The diluent of lyophilized vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.
Study NCT02009878 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: tolvaptan
Description: Subjects will receive a single dose of 3.75, 7.5 or 15 mg of tolvaptan on study Day 1
Study NCT02410694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Study NCT02410694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Study NCT02410694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study NCT03665363 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SCOPE
Description: SCOPE is a internet-delivered, coach-guided, psychoeducational intervention, intended to serve as a first-line intervention for intellectually able adolescents and young adults with ASD. The SCOPE program is based on information comprising neuropsychology, pedagogy, and also interdisciplinary clinical experience regarding ASD. The content is aimed at providing information about typical and specific impairments of ASD, as well as the associated strengths.
Study NCT03665363 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self-study
Description: Active control consisting of directed self-studies on internet.
Study NCT04173741 — intervention group
Intervention type: OTHER
Intervention: USG measurement
Description: IVC was visualized in the subxiphoid long axis by using convex probe (5-1 MHz). Diameters of IVC was measured 2 cm caudally to the junction of hepatic vein in M-mode. IJV diameter was measured in the short axis by using linear probe (12-5 MHz) and M-mode. IJV visualized in the junction of cricothyroid membrane level and midclavicular line. Maximum and minimum diameter values were measured in the M mode. Distensibility (maximum diameter - minimum diameter / minimum diameter) and collapsibility (maximum diameter - minimum diameter / maximum diameter) indices were calculated after USG measurements were done.
Study NCT02504788 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: hippocampal-sparing WBRT
Study NCT04269395 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MAL Cream
Description: No intervention will be administered as a part of this study. Participants who received MAL cream in RD.06.SPR.112199 study will be rolled over in the study.
Study NCT04269395 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle cream
Description: No intervention will be administered as a part of this study. Participants who received vehicle cream in RD.06.SPR.112199 study and achieved complete response, will be rolled over in the study.
Study NCT03512548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relacorilant 350mg
Description: Relacorilant 350mg
Study NCT03512548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole 200 mg
Study NCT03512548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relacorilant 300mg
Description: Relacorilant 300mg
Study NCT02128126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISA101/ISA101b
Description: Four dose levels ISA101/ISA101b
Study NCT01200784 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotinamide
Description: dosage
Study NCT01200784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotinamide
Description: dosage
Study NCT01764633 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen.
Study NCT01764633 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen.
Study NCT00433329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosentan
Description: Oral bosentan 62.5 mg BID first 4 weeks followed by 24 weeks of 125 mg BID if the 62.5 mg BID dose was well tolerated
Study NCT00433329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Oral sildenafil 20 mg TID in patients who do not reach the 6-MWT distance threshold at Week 16
Study NCT01575210 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP mask
Description: A new vent CPAP mask system will be used in this trial.
Study NCT01575210 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP mask
Description: A new vent CPAP mask system will be used in this trial
Study NCT02183090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam ampoule
Study NCT02183090 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meloxicam tablet
Study NCT02296242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BVD-523
Description: Oral, multiple escalating doses, twice daily, for 21 days in each treatment cycle
Study NCT04113915 — intervention group
Intervention type: DRUG
Intervention: triple therapy
Description: Effect of treatment on immunity to obtain infection with hepatitis B\&C
Study NCT04113915 — intervention group
Intervention type: DRUG
Intervention: Steroids
Description: Oral or parenteral steroid therapy for ITP
Study NCT00257010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Almotriptan Malate
Description: Patients will take one 12.5 mg almotriptan malate tablet by mouth after the onset of migraine headache pain
Study NCT00883675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel-Carboplatin
Description: Docetaxel: 75 mg/m2 over 1 hour every 3 weeks for 3 doses Carboplatin AUC 5.5 over 0.5 to 1 hour every 3 weeks for 3 doses
Study NCT00984750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetyl-L-carnitine/statin (simvastatin)
Description: acetyl-L-carnitine: 4 tablets of 500 mg a day~simvastatin: 10 to 20 mg/day as deemed clinically appropriate and according to tolerability
Study NCT00984750 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo: 4 tablets of 500 mg a day simvastatin: 10 to 20 mg/day as deemed clinically appropriate and according to tolerability
Study NCT04545905 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ANC surveillance
Description: Clinic-based testing of all pregnant women during antenatal care visits.
Study NCT02436460 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AbGn-168H
Description: Humanized monoclonal antibody
Study NCT04075929 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Training effects on aerobic output
Description: The cyclists were allowed to perform ad libitum low intensity (LIT) in addition to high intensity (HIT) sessions that were determined to each group. The cyclists completed 12 supervised HIT sessions during the intervention period, three HIT sessions per week with at least 48 hours between each HIT-session. All HIT sessions were performed as supervised group training sessions. Each HIT session started with an individual 30 minutes' warm up at low intensity (55-70% HRmax) interspersed by freely chosen progressive sprints. For all groups the power output during the recovery periods was 50 % of the power output used during work intervals. The cyclists in all groups were instructed to perform each interval session at their maximal sustainable intensity. Each session ended with 15-20 minutes' cool down (55-70% HRmax). All HIT sessions were supervised and performed in groups on the University of Agder's (UiA) premises at Spicheren fitness center in Kristiansand.
Study NCT02562326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BioChaperone insulin lispro
Description: Injection immediately before the start of the individualised standard meal
Study NCT02562326 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humalog®
Description: Injection immediately before the start of the individualised standard meal
Study NCT01551979 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: intermittent Theta Burst (iTBS) pattern (20 trains of 10 bursts given with 8s intervals) will be applied at 80% of active motor threshold. Each participant will receive 600 pulses per session.~Sham participants will undergo the same procedures as those in the active rTMS group.
Study NCT01551979 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: intermittent Theta Burst (iTBS) pattern (20 trains of 10 bursts given with 8s intervals) will be applied at 80% of active motor threshold. Each participant will receive 600 pulses per session.~Sham participants will undergo the same procedures as those in the active rTMS group.
Study NCT04043000 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Super 13 Pro & Prebiotics
Description: Super 13 Pro \& Prebiotics was given three times a day for four weeks.
Study NCT04043000 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Super 13 Pro & Prebiotics
Description: Super 13 Pro \& Prebiotics was given three times a day for four weeks.
Study NCT04095169 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Complement C3d test (blood sample)
Description: Evaluation of C3d levels in EDTA samples from participants
Study NCT00949156 — intervention group
Intervention type: PROCEDURE
Intervention: Different surgical approach and techniques being used to treat three subtype of CP
Description: According to the presurgical MRI, with the analysis of the morphological characteristic of three subtype of CP, different surgical approach and intrasurgical skills were used to treat tumors with trying to total remove tumor and avoid the hypothalamus injury.
Study NCT01497977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: phytoestrogens
Description: The red clover capsule consisted of 4 isoflavones: biokain A (23mg), daidzein (1mg), formononetin (15mg) and genistein (1mg).
Study NCT01497977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: phytoestrogens
Description: The soya daily dose contained 2 isoflavones: genistein (39mg) and daidzein (1mg).
Study NCT01826708 — intervention group
Intervention type: BIOLOGICAL
Group type: NO_INTERVENTION
Intervention: Identification of breakpoints
Description: Identification of breakpoints in Molecular Biology : demonstration of a chimeric sequence corresponding to a junction region between the two chromosomes
Study NCT00663741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib (Nexavar, BAY43-9006)
Description: Sorafenib (400 mg bid) + S-1 (40 mg/m2 bid, 3 weeks on / 2 weeks off) + CDDP (60 mg/m2 on Day 8) / 35 days / cycle
Study NCT00663741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib (Nexavar, BAY43-9006)
Description: Sorafenib (400 mg bid) + S-1 (25 mg/m2 bid, 3weeks on / 1 week off) + CDDP (75 mg/m2 on Day 1) / 28 days / cycle
Study NCT00663741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib (Nexavar, BAY43-9006)
Description: Sorafenib (400 mg bid) + S-1 (40 mg/m2 bid, 3 weeks on / 1 week off) + CDDP (75 mg/m2 on Day 1) / 28 days cycle
Study NCT03105830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iv paracetamol
Description: iv paracetamol
Study NCT02738190 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albumin
Description: Albumin 5% added to blood priming solution
Study NCT02738190 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fresh Frozen Plasma
Description: Fresh Frozen Plasma added to blood priming solution
Study NCT01194609 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immune cell
Description: InnoLak two consecutive weeks every 3 weeks for 3 times
Study NCT01194609 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low dose radiation
Description: 20cGy whole body radiation every three weeks for three times
Study NCT00743548 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IB = Interdental brush, the intervention
Description: IB is a small multi-tufted brush on a wire attached to a long angled handle that is inserted in a horizontal plane between the teeth. The IB is inserted once and removed.
Study NCT00743548 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: DF = Dental floss, the positive control
Description: DF is waxed dental floss; nylon covered with a water soluble unflavoured wax to facilitate easier access the contact points of teeth. DF is rubbed against the interproximal surfaces of the teeth 2-4 times on each surface.